Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) unit Fosun Kairos (Shanghai) Biological Technology's registration application for brexucabtagene autoleucel injection was accepted by China's National Medical Products, a Wednesday Hong Kong bourse filing said.
The declared indication for this application is for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.